ABSTRACT
Objective To investigate the efficacy and safety of atorvastatin combined with benazepril in the treatment of proteinuria in patients with IgA nephropathy ,so as to provide guidance for clinical medication .Methods Eighty patients with IgA nephropathy were selected ,and they were randomly divided into the observation group and control group according to random number table , with 40 patients in each group .The observation group was treated with atorvastatin combined with benazepril ,and the control group was treated with benazepril .The treatment effect of the two groups was compared.Results Before treatment,the 24h urinary protein,mean arterial pressure,serum creat-inine,blood urea nitrogen,and blood potassium between the two groups had no statistically significant differences (t=0.125,1.273,0.321,0.207,0.719,all P>0.05).After treatment,the 24h urine protein and mean arterial blood pressure in the two groups were lower than those before treatment , and the differences were statistically significant (t=2.735,6.145,3.434,4.501,all P<0.05),which in the observation group were lower than those in the control group,the differences were statistically significant (t=3.121,2.170,all P<0.05).The changes of serum creatinine, blood urea nitrogen and serum potassium in the two groups had no statistically significant differences (all P>0.05) .Conclusion Atorvastatin combined with benazepril in the treatment of IgA nephropathy can significantly decrease urinary protein level,without the adverse reactions of increased urea nitrogen ,creatinine and hyperkalemia ,which is worthy of popularization and application .
ABSTRACT
Objective To summarize analysis of respiratory tract mycoplasma infection in patients with oral azithromycin,oral and intravenous erythromycin treatment the clinical effect and safety.Methods From April 2014 to September 2016 received during the period of 120 patients with respiratory tract mycoplasma infection as the research object,were randomly divided into oral azithromycin, oral erythromycin group and intravenous erythromycin group,all patients were retrospectively analyzed the clinical therapeutic effects and adverse reactions occur.Results The total effective rate in treatment,oral azithromycin is higher than oral and intravenous treatment of erythromycin,Signs and symptoms in the incidence of adverse reactions and improve the time aspect,oral azithromycin is lower than the oral and intravenous treatment of erythromycin,diff there is statistical significance(P<0.05).Conclusion For respiratory tract mycoplasma infection adopt oral azithromycin compared with oral and intravenous erythromycin treatment,the effect is better,shorter symptom improvement,higher security,worthy of clinical popularization and application.